Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 141

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 141
---
crease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by investors participating in this offering, total consideration paid by all stockholders and the average price per share paid by all stockholders by $ million, assuming the assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting the underwriting discounts and commissions payable by us. The table above assumes no exercise of the underwriters’ option to purchase additional shares of common stock in this offering. If the underwriters were to fully exercise their option to purchase additional shares of common stock from us, the percentage of our common stock held by existing stockholders after this offering would be reduced to % of the total number of shares of our common stock outstanding after this offering, and the percentage of our common stock held by new investors would be increased to % of the total number of shares of our common stock outstanding after this offering. 92

The number of shares of our common stock to be outstanding after this offering is based on 85,094,050 shares of common stock outstanding as of June 30, 2025, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into 78,072,306 shares of common stock upon the closing of this offering and excludes:

| • |     | 11,923,082 shares of common stock issuable upon the exercise of outstanding stock options under our 2023 Plan as 
 of June 30, 2025, at a weighted-average exercise price of $1.50 per share;                                       |

| • |     | 779,500 shares of common stock issuable upon the exercise of outstanding stock options under our 2018 Plan as of 
 June 30, 2025, at a weighted-average exercise price of $2.38 per share;                                          |

| • |     | 290,000 shares of common stock issuable upon the exercise of outstanding stock options under our 2017 Plan as of 
 June 30, 2025, at a weighted-average exercise price of $1.79 per share;                                          |

| • |     | 695,961 shares of our common stock issuable upon the exercise of Class A common stock warrants outstanding                                                              
 as of June 30, 2025, with an exercise price of $0.01 per share,